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Available online 22 October 2015This is a case presentation of a 57-year-old male patient treated
for prostate cancer before the advent of novel agents such as
abiraterone and enzalutamide. The patient presented with
obstructive lower urinary tract symptoms in the year 2000. Digital
rectal examination revealed hard enlarged prostate with mobile
rectal mucosa. Prostate-speciﬁc antigen (PSA) was 36 ng/mL,
transrectal ultrasound guided biopsy revealed S/O adenocarcinoma
and a high Gleason score (4þ3), CT scan of the pelvis found mild
prostatomegaly with no LAP, and bone scan revealed nometastases.
Radical prostatectomy was initially planned but was aborted whenFig. 1. Treatment history and dis
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p2287-8882 e2287-903Xfurther examination revealed two enlarged lymph nodes and the
frozen section was negative for malignancy. Despite being given
hormonal agents and chemotherapy, his disease progressed, and
the patient died in 2010 (Fig. 1).
The treatment landscape for castration-resistant prostate cancer
(CRPC) has evolved dramatically, particularly over the last decade.
Prior to the era of novel agents, patients were treated with high
dose secondary hormonal agents such as ketoconazole, amino-
glutethimide, corticosteroids and antioestrogens such as fosfesterol
oestrogen (Honvan®). Estramustine phosphate was also used with
modest effect.1 PCAPES, a Chinese herbal medicine was also very
popular back then.
In one study byWilliams et al, oestrogen therapy resulted in 92%
subjective improvement.2 Among patients who were hormone re-
fractory, 11% had a decline in PSA levels and 33% had a subjective
response. In Citrin et al,3 3 out of 18 patients on oestrogen hadmoreease progression of patient
Conference Abstract / A case study from India S21than 50% reduction in plasma PSA levels, while in Ferro et al,4 13 out
of 29 patients on oestrogen hadmore than 50% reduction in plasma
PSA. A study by Orlando et al reported that low dose oral oestrogen
improved outcome in patients who became refractory to chemical /
surgical orchiectomy and anti-androgen.5 In one phase III trial, 27%
of patients on anti-androgen withdrawal and ketoconazole had a
PSA response compared to 11% of patients on anti-androgen
withdrawal only.6 For estramustine phosphate, 35% of patients
with advanced carcinoma of the prostate had an objective remis-
sion. A speciﬁc cytostatic effect of estramustine phosphate, may be
responsible for remissions in some patients who have become
resistant to conventional hormonal treatment. This cytostatic ef-
fect, however, is not clearly understood. Common adverse effects
associated with ketoconazole include nausea, dry skin, and fatigue.
Patients on oestrogen therapy may experience cardiovascular
toxicity and thromboembolism.
In recent years, novel agents (such as abiraterone and enzalu-
tamide) together with chemotherapy have changed the treatment
approach for CRPC.7,8 This means that patients with advanced
prostate cancer can expect improved quality of life, prolonged re-
missions and increased survival.
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